Transcripts PHAXIAM Therapeutics S.A.

Equities

End-of-day quote Euronext Paris Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
3.025 ^EUR	+0.83%		+4.31%	-34.24%

Apr. 15	Phaxiam initiates trial in infective endocarditis	CF
Apr. 15	PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	CI

Mar. 21

No results for this search